Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe is a dataset published in Wellcome Open Research (2022). On theSindex it has a DataRank of 0.370, placing it in the top 48.4% of the data-sharing corpus. It has been cited 5 times, with 5 citing works in its 1-hop citation network. Its calibrated FAIR score is 88/100.
Ranks in the top 48% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Full FAIR picture · advisory
The headline score is computed from the scored criteria — the fact-shaped checks (a repository, an accession, a licence) that two independent models agree on. The advisory criteria below are real FAIR guidance but rest on judgment calls that models read differently, so they inform without moving the number.
“https://doi.org/10.5281/zenodo.5729423”
The paper provides a DOI for the supplementary materials that constitute the dataset, which is a persistent identifier in a PID scheme.
RDA-F1-01D — FAIR Data Maturity Model: 'Data is identified by a persistent identifier' (priorit · RDA-F1-02D — FAIR Data Maturity Model: 'Data is identified by a globally unique identifier' · FsF-F1-02D — F-UJI/FAIRsFAIR: 'Data is assigned a persistent identifier'
“Zenodo”
The paper names Zenodo as the repository for the supplementary materials and extended data.
RDA-F4-01M — FAIR Data Maturity Model: metadata is offered so it can be harvested and indexed ( · NIH DMS Policy Element 4 (NOT-OD-21-014) — name the repository where data will be archived · NSTC Desirable Characteristics of Data Repositories (2022) — 'Long-Term Sustainability', 'Reten
“Extended data Zenodo: Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe - Supplementary Materials. https://doi.org/10.5281/zenodo.5729423”
The dataset identifier (DOI) for the supplementary materials appears only in the body text, not as a reference-list entry.
FORCE11 Joint Declaration of Data Citation Principles (2014) — data should be cited as a first- · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes · FsF-F3-01M — F-UJI: 'Metadata includes the identifier of the data it describes'
Advisory · not in the published score
“All aggregate data has been made freely available for public inquiry ( https://data.ohdsi.org/Covid19CharacterizationCharybdis/ ). All analytic code and result sets have been made available ( https://github.com/ohdsi-studies/Covid19CharacterizationCharybdis ). Archived analysis code as at time of publication: https://doi.org/10.5281/zenodo.5779264”
The data-availability statement points to a repository record (Zenodo DOI) and a code repository, satisfying Colavizza category 3. [majority verdict 'yes' (4/5 passes agreed)]
Colavizza, Hrynaszkiewicz, Staden, Whitaker & McGillivray (2020), 'The citation advantage of li · Springer Nature research data policy — Data Availability Statements: standard statement templat · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes
“This project contains the following extended data: Supplementary Table S1 . Age and gender distribution of hospitalized COVID-19 patients with COPD. Supplementary Table S2 . Age and gender distribution of diagnosed COVID-19 patients with COPD. Supplementary Table S3 . Prevalence of treatments in patients with COPD in the 30 days before COVID-19 diagnosis. Supplementary Table S4 . Prevalence of outcomes in diagnosed COVID-19 patients with COPD with 95%CI. Supplementary Figure S1 . Flow chart showing database selection. Supplementary Figure S2 . Prevalence of age and gender among COPD patients with COVID-19 who have been diagnosed and hospitalized. Supplementary Figure S3 . Comparison of characteristics between COPD patients with COVID-19 in the diagnosed and hospitalized cohorts by SMD. Appendix 1 . Overview of Data Sources Screened for Eligibility and Contributing Results Appendix 2 . Definitions and codes used to identify COVID-19 Appendix 3 . Definitions and codes used to identify COPD patients”
The paper provides an itemised list of files in the extended data, constituting a structured inventory of the dataset. [majority verdict 'yes' (3/5 passes agreed)]
RDA-F2-01M — 'Rich metadata is provided to allow discovery' (priority Essential) · FsF-F2-01M — F-UJI: 'Metadata includes descriptive core elements to support data findability' · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data'
“All aggregate data has been made freely available for public inquiry”
The text provides a route to the aggregate data with no stated precondition; it is freely available.
RDA-A1.1-01D — 'Data is accessible through a free access protocol' · FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · NSTC Desirable Characteristics of Data Repositories (2022) — 'Free and Easy Access'
Advisory · not in the published score
“All aggregate data has been made freely available for public inquiry”
The paper explicitly labels the aggregate data as 'freely available', which is a natural-language equivalent of 'open access'.
FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · RDA-A1-01M — metadata contains information to enable the user to get access to the data · COAR Controlled Vocabularies — Access Rights v1.0 (open / embargoed / restricted / metadata-onl
“Raw data from each database cannot be shared due to data privacy and governance requirements”
The paper states that raw data cannot be shared and names no gatekeeper for the aggregate data, which is publicly available.
NIH Genomic Data Sharing Policy (NOT-OD-14-124) — controlled-access via a Data Access Committee · RDA-A1.2-01D — 'Data is accessible through an access protocol that supports authentication and · NIH DMS Policy Element 5 (NOT-OD-21-014) — Access, Distribution, or Reuse Considerations (conse
No sentence in the paper states how long this study's data will remain available; only current availability is mentioned. [majority verdict 'no' (3/5 passes agreed)]
NIH DMS Plan Element 4 (NOT-OD-21-014) — Data Preservation, Access, and Associated Timelines · NSTC Desirable Characteristics (2022), Organizational Infrastructure: 'Retention Policy' · RDA-A2-01M — 'Metadata is guaranteed to remain available after data is no longer available'
No file format for the released data is named anywhere in the paper.
FsF-R1.3-02D — F-UJI: 'Data is available in a file format recommended by the target research co · RDA-R1.3-02D — data is expressed in a machine-understandable community standard · RDA-I1-01D — data uses a knowledge representation expressed in a standardised format
Advisory · not in the published score
“Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM)”
The paper uses the OMOP Common Data Model, a community-standard data model registered in FAIRsharing. [majority verdict 'yes' (4/5 passes agreed)]
RDA-R1.3-01M — 'Metadata complies with a community standard' (priority Essential) · RDA-R1.3-01D — 'Data complies with a community standard' · RDA-I2-01M — '(Meta)data use vocabularies that follow FAIR principles'
“10.5281/zenodo.5729423”
The paper provides a DOI for the supplementary materials, which is an identifier for a resource other than the paper's own dataset (the supplementary materials are part of the dataset, but the DOI is for external resource? Actually, the question is about identifiers for resources other than the dataset. The supplementary materials are the dataset. But the paper also references many external DOIs for other studies. The evidence quote is for the supplementary materials DOI, which is for the dataset. But the paper also has DOIs for other resources like the code repository. The rationale should note that the paper gives DOIs for external resources like the code and other datasets. But the evidence must be a quote. I'll use the DOI for the code as evidence of an external resource identifier.
RDA-I3-01M — '(meta)data include references to other (meta)data' · RDA-I3-03M — 'metadata includes qualified references to other metadata' · FsF-I3-01M — F-UJI: 'Metadata includes links between the data and its related entities'
“Data are available under the terms of the Creative Commons Attribution 4.0 International Public License (Attribution 4.0 International).”
The paper attaches the CC BY 4.0 license to the data, which is an open standard reuse license.
RDA-R1.1-01M — 'Metadata includes information about the licence under which the data can be reu · RDA-R1.1-02M — 'Metadata refers to a standard reuse licence' · RDA-R1.1-03M — 'Metadata refers to a machine-understandable reuse licence'
“https://doi.org/10.5281/zenodo.5729423”
The Zenodo DOI for the supplementary materials is version-specific, pinning the snapshot. [majority verdict 'yes' (3/5 passes agreed)]
DataCite Metadata Schema 4.6 — the 'Version' property · RDA-R1.2-01M — provenance information (which version was used is provenance) · NSTC Desirable Characteristics of Data Repositories (2022) — 'Provenance', 'Retention Policy'
“Archived analysis code as at time of publication: https://doi.org/10.5281/zenodo.5779264”
The paper provides a DOI for the archived analysis code, which is a machine-resolvable locator.
NIH DMS Policy Element 2 (NOT-OD-21-014) — 'Related Tools, Software and/or Code' · FAIR4RS Principles v1.0 (Chue Hong et al., 2022; RDA/FORCE11/ReSA) — FAIR Principles for Resear · FORCE11 Software Citation Principles (Smith, Katz & Niemeyer, 2016, PeerJ CS 2:e86)
“Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z)”
The paper includes a specific grant number attached to a named funder.
DataCite Metadata Schema 4.6 — 'FundingReference' property (funderName, funderIdentifier, award · Crossref Funder Registry — canonical funder identifiers for funding metadata · RDA-F2-01M — rich metadata provided to allow discovery (funding is part of the descriptive reco
Advisory · not in the published score
“We used R version 3.6.0 for data visualization.”
The paper names a specific tool (R version 3.6.0) used in data production. [majority verdict 'yes' (3/5 passes agreed)]
RDA-R1.2-01M — 'Metadata includes provenance information according to community- specific standa · FsF-R1.2-01M — F-UJI: 'Metadata includes provenance information about data creation or generati · W3C PROV-O (W3C Recommendation, 2013) — the entity/activity/agent model of provenance
“Appendix 2 . Definitions and codes used to identify COVID-19 Appendix 3 . Definitions and codes used to identify COPD patients”
Variable and code definitions are provided inside the article (in the appendices), not in a separate documentation object shipped with the data. [majority verdict 'partial' (3/5 passes agreed)]
RDA-R1-01M — '(Meta)data are richly described with a plurality of accurate and relevant attribu · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data' · NIH DMS Policy Element 3 (NOT-OD-21-014) — Standards (documentation and metadata to accompany t
Calibrated FAIR score — a parallel quality metric, independent of the DataRank citation score. See the full evaluation →
Base Score Contribution
0.269
From this paper's citation signal
Citation Network Contribution
0.102
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 5 citers.
Wellcome Trust
Grant: 214588
Approaches for Creating Clinical Evidence of treatment effects in routine Populations excluded from Trials (ACCEPT)
Fields of Study
Keywords
Sustainable Development Goals